A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
The purpose of this study is to evaluate the safety of different doses of risankizumab and determine how well it works in subjects with moderate to severe Crohn’s disease.
Study phase: III
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
Male or female aged ? 18 to ? 80 years
Confirmed diagnosis of CD
Please contact study coordinator for additional inclusion and exclusion criteria
Primary disease category: Digestive System
Secondary disease categories: Autoimmune Disorders
Sponsor: AbbVie, Inc.
Projected enrollment dates: February 2018 to December 2021
Official study title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment